SARTORIUS AG-VORZUG (SRT3.DE) Fundamental Analysis & Valuation

FRA:SRT3 • DE0007165631

Current stock price

206.8 EUR
-8.7 (-4.04%)
Last:

This SRT3.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. SRT3.DE Profitability Analysis

1.1 Basic Checks

  • In the past year SRT3 was profitable.
  • SRT3 had a positive operating cash flow in the past year.
  • Each year in the past 5 years SRT3 has been profitable.
  • SRT3 had a positive operating cash flow in each of the past 5 years.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • With a Return On Assets value of 1.60%, SRT3 is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • SRT3 has a worse Return On Equity (5.73%) than 61.11% of its industry peers.
  • SRT3 has a worse Return On Invested Capital (4.97%) than 66.67% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for SRT3 is below the industry average of 9.34%.
  • The 3 year average ROIC (4.49%) for SRT3 is below the current ROIC(4.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.6%
ROE 5.73%
ROIC 4.97%
ROA(3y)1.51%
ROA(5y)3.97%
ROE(3y)6.23%
ROE(5y)15.62%
ROIC(3y)4.49%
ROIC(5y)9.01%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • With a Profit Margin value of 4.38%, SRT3 is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • SRT3's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 15.34%, SRT3 perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of SRT3 has declined.
  • With a decent Gross Margin value of 46.26%, SRT3 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 15.34%
PM (TTM) 4.38%
GM 46.26%
OM growth 3Y-16.16%
OM growth 5Y-5.98%
PM growth 3Y-35.4%
PM growth 5Y-13.41%
GM growth 3Y-3.93%
GM growth 5Y-2.18%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1

2. SRT3.DE Health Analysis

2.1 Basic Checks

  • SRT3 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, SRT3 has about the same amount of shares outstanding.
  • SRT3 has more shares outstanding than it did 5 years ago.
  • SRT3 has a better debt/assets ratio than last year.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.26 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • SRT3's Altman-Z score of 2.26 is in line compared to the rest of the industry. SRT3 outperforms 44.44% of its industry peers.
  • SRT3 has a debt to FCF ratio of 10.84. This is a negative value and a sign of low solvency as SRT3 would need 10.84 years to pay back of all of its debts.
  • SRT3 has a worse Debt to FCF ratio (10.84) than 61.11% of its industry peers.
  • A Debt/Equity ratio of 1.24 is on the high side and indicates that SRT3 has dependencies on debt financing.
  • The Debt to Equity ratio of SRT3 (1.24) is worse than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF 10.84
Altman-Z 2.26
ROIC/WACC0.58
WACC8.56%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that SRT3 may have some problems paying its short term obligations.
  • SRT3 has a Current ratio of 0.90. This is amonst the worse of the industry: SRT3 underperforms 88.89% of its industry peers.
  • A Quick Ratio of 0.50 indicates that SRT3 may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.50, SRT3 is doing worse than 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.5
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

6

3. SRT3.DE Growth Analysis

3.1 Past

  • SRT3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.46%, which is quite impressive.
  • SRT3 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.76% yearly.
  • Looking at the last year, SRT3 shows a small growth in Revenue. The Revenue has grown by 4.66% in the last year.
  • SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.66% yearly.
EPS 1Y (TTM)83.46%
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
Revenue 1Y (TTM)4.66%
Revenue growth 3Y-5.37%
Revenue growth 5Y8.66%
Sales Q2Q%2.29%

3.2 Future

  • SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.94% on average per year.
EPS Next Y21.83%
EPS Next 2Y21.56%
EPS Next 3Y19.17%
EPS Next 5Y16.39%
Revenue Next Year6.85%
Revenue Next 2Y8.73%
Revenue Next 3Y9.02%
Revenue Next 5Y8.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

1

4. SRT3.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 43.26, the valuation of SRT3 can be described as expensive.
  • Based on the Price/Earnings ratio, SRT3 is valued a bit more expensive than the industry average as 72.22% of the companies are valued more cheaply.
  • When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (24.88), we can say SRT3 is valued expensively.
  • A Price/Forward Earnings ratio of 35.51 indicates a quite expensive valuation of SRT3.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 72.22% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. SRT3 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 43.26
Fwd PE 35.51
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • SRT3's Enterprise Value to EBITDA is on the same level as the industry average.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as SRT3.
Industry RankSector Rank
P/FCF 39.19
EV/EBITDA 20.63
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as SRT3's earnings are expected to grow with 19.17% in the coming years.
PEG (NY)1.98
PEG (5Y)24.54
EPS Next 2Y21.56%
EPS Next 3Y19.17%

4

5. SRT3.DE Dividend Analysis

5.1 Amount

  • SRT3 has a yearly dividend return of 0.43%, which is pretty low.
  • SRT3's Dividend Yield is a higher than the industry average which is at 0.56.
  • Compared to an average S&P500 Dividend Yield of 1.90, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.43%

5.2 History

  • On average, the dividend of SRT3 grows each year by 15.65%, which is quite nice.
Dividend Growth(5Y)15.65%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 32.71% of the earnings are spent on dividend by SRT3. This is a low number and sustainable payout ratio.
  • The dividend of SRT3 is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP32.71%
EPS Next 2Y21.56%
EPS Next 3Y19.17%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SRT3.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS AG-VORZUG

FRA:SRT3 (3/27/2026, 5:36:15 PM)

206.8

-8.7 (-4.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners1.97%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.49B
Revenue(TTM)3.54B
Net Income(TTM)155.00M
Analysts80
Price Target376.45 (82.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.43%
Yearly Dividend0.73
Dividend Growth(5Y)15.65%
DP32.71%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.19%
Min EPS beat(2)4.83%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)-0.57%
Min EPS beat(4)-10.52%
Max EPS beat(4)7.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.53%
Min Revenue beat(2)0.24%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)2.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.27%
PT rev (3m)8.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.75%
EPS NY rev (3m)-3.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-1.39%
Valuation
Industry RankSector Rank
PE 43.26
Fwd PE 35.51
P/S 4.38
P/FCF 39.19
P/OCF 18.5
P/B 5.72
P/tB N/A
EV/EBITDA 20.63
EPS(TTM)4.78
EY2.31%
EPS(NY)5.82
Fwd EY2.82%
FCF(TTM)5.28
FCFY2.55%
OCF(TTM)11.18
OCFY5.41%
SpS47.25
BVpS36.15
TBVpS-34.61
PEG (NY)1.98
PEG (5Y)24.54
Graham Number62.35
Profitability
Industry RankSector Rank
ROA 1.6%
ROE 5.73%
ROCE 7%
ROIC 4.97%
ROICexc 5.35%
ROICexgc 20.27%
OM 15.34%
PM (TTM) 4.38%
GM 46.26%
FCFM 11.17%
ROA(3y)1.51%
ROA(5y)3.97%
ROE(3y)6.23%
ROE(5y)15.62%
ROIC(3y)4.49%
ROIC(5y)9.01%
ROICexc(3y)4.83%
ROICexc(5y)9.64%
ROICexgc(3y)16.7%
ROICexgc(5y)28.15%
ROCE(3y)6.33%
ROCE(5y)12.7%
ROICexgc growth 3Y-19.62%
ROICexgc growth 5Y-7.23%
ROICexc growth 3Y-29.84%
ROICexc growth 5Y-12.08%
OM growth 3Y-16.16%
OM growth 5Y-5.98%
PM growth 3Y-35.4%
PM growth 5Y-13.41%
GM growth 3Y-3.93%
GM growth 5Y-2.18%
F-Score7
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF 10.84
Debt/EBITDA 3.49
Cap/Depr 105.19%
Cap/Sales 12.49%
Interest Coverage 3
Cash Conversion 86.94%
Profit Quality 254.9%
Current Ratio 0.9
Quick Ratio 0.5
Altman-Z 2.26
F-Score7
WACC8.56%
ROIC/WACC0.58
Cap/Depr(3y)122.42%
Cap/Depr(5y)145.08%
Cap/Sales(3y)13.7%
Cap/Sales(5y)13.08%
Profit Quality(3y)357.39%
Profit Quality(5y)249.46%
High Growth Momentum
Growth
EPS 1Y (TTM)83.46%
EPS 3Y-20.66%
EPS 5Y1.76%
EPS Q2Q%21.15%
EPS Next Y21.83%
EPS Next 2Y21.56%
EPS Next 3Y19.17%
EPS Next 5Y16.39%
Revenue 1Y (TTM)4.66%
Revenue growth 3Y-5.37%
Revenue growth 5Y8.66%
Sales Q2Q%2.29%
Revenue Next Year6.85%
Revenue Next 2Y8.73%
Revenue Next 3Y9.02%
Revenue Next 5Y8.94%
EBIT growth 1Y38.38%
EBIT growth 3Y-20.66%
EBIT growth 5Y2.17%
EBIT Next Year85.03%
EBIT Next 3Y33.54%
EBIT Next 5Y24.23%
FCF growth 1Y-30.23%
FCF growth 3Y23.14%
FCF growth 5Y7.81%
OCF growth 1Y-14.26%
OCF growth 3Y4.46%
OCF growth 5Y10.35%

SARTORIUS AG-VORZUG / SRT3.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 43.26 and the Price/Book (PB) ratio is 5.72.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.